MedTrace Logo

Ketamine for Treatment-resistant Depression: A Multicentric Clinical Trial in Mexican Population

NCT01868802 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2015-03-17

No results posted yet for this study

Summary

A randomized multicentric parallel arms study involving the use of ketamine for treatment-resistant depression will be held at three national health provider clinics in the Mexican population. The purpose of this study is to determine whether clinical response seen in previous studies is replicable in this population.

Conditions

  • Depressive Disorder,
  • Treatment-Resistant Depression

Interventions

DRUG

Ketamine

A single dose of 0.5mg/kg intravenous ketamine infusion will be administered over 40 minutes.

DRUG

Placebo

Saline at 0.9% intravenous infusion will be administered over 40 minutes.

Sponsors & Collaborators

  • Paul J. Lamothe

    lead OTHER

Principal Investigators

  • Paul J Lamothe, M.D. · American British Cowdray Medical Center

  • David N Lopez-Garza, M.D. · American British Cowdray Medical Center

  • Manuel Ruiz-Alvarez, M.D. · American British Cowdray Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-09-30
Primary Completion
2016-05-31

Countries

  • Mexico

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01868802 on ClinicalTrials.gov